Ultragenyx Pharmaceutical(NASDAQ) RARE

Ultragenyx makes medicines for people with rare genetic diseases. These illnesses often have no other treatment options. The company helps patients manage serious conditions through science.

What Does Ultragenyx Sell?

• Crysvita: Antibody treating bone disorders by stopping phosphate loss; it generated $93 million in combined sales and royalties in Q1 2026.
• Dojolvi: Synthetic fat source for patients who cannot break down certain oils for energy; accounted for $18 million in Q1 2026 revenue.
• Evkeeza: Injection that blocks a protein to lower extreme cholesterol levels; earned $18 million in Q1 2026 product sales.
• Mepsevii: Enzyme replacement therapy for a rare metabolic condition affecting skeletal health; contributed $7 million to Q1 2026 sales.

Strategic Deals and Partnerships

• Sold future royalty rights for its bone disease drug to OMERS in November 2025 to raise $400 million.
• Acquired GeneTx in July 2022 to secure the rights for a new neurogenetic drug candidate.
• Partnered with Regeneron in January 2022 to market a cholesterol therapy in regions outside the United States.
• Launched a restructuring plan in February 2026 to cut the workforce by 10% and save costs.

Diverse Scientific Foundations

Ultragenyx uses multiple scientific platforms, such as gene therapy and small molecules, to develop its medicines. This approach allows the company to address different rare diseases through tailored biological methods.

Tracking Recent Performance

• Total revenue reached $136 million in Q1 2026, down 2.4% from the same period in 2025.
• Net loss worsened to $185 million in Q1 2026, a 22.5% increase from a year earlier.
• Operating cash flow deficit deepened 18.3% to $197 million during the first quarter of 2026.
• Cash and marketable securities totaled $534 million as of March 31, 2026.
• Market cap fell to $2.1 billion in Q1 2026, down 39.6% year-over-year.

Bottom Line

Ultragenyx has evolved into a commercial business with four approved products for rare diseases. The company is currently streamlining its operations to focus resources on its most promising genetic medicine candidates.